Abstract Title: currently loading...

information currently loading...

Loading ... please wait
timer Loading ... please wait

Free Paper Session 17: AMD & New Drug Treatment & Technology

08:30 - 10:00 | 08 September | Room: Amphitheatre Havane

Back to Previous

08:30A phase 1/2 optogenetic retinal gene therapy clinical trial for non-syndromic retinitis pigmentosa (PIONEER study)
S. Degli Esposti United Kingdom
08:36Efficacy and safety of abicipar compared with ranibizumab in the treatment of neovascular age-related macular degeneration: results from the cedar and sequoia phase 3 clinical trials
E. Souied France
08:42OTS APP: improving the ocular trauma management
H. Ocampo Colombia
08:48Solid lipid nanoparticles improve the diclofenac availability in vitreous after intraocular injection
M. Abrishami Iran, Islamic Republic of
08:54Anti-angiogenic and anti-scarring dual action of an anti-fibroblast growth factor-2 aptamer in animal models of retinal disease
Y. Nakamura Japan
09:00Based on the real-life data of Turkey; one-year results of treatment with anti-vascular endothelial growth factor for exudative age-related macular degeneration in eyes with different baseline visual acuity. Bosphorus retina study group, report 6
M. Ozturk Turkey
09:06One-year efficacy of anti-vascular endothelial growth factor agents in patients with neovascular age-related macular degeneration: a meta-analysis and meta-regression
V. Sarao Italy
09:12Correlation of OCT-A and Angiography in the diagnosis and classification of neovascular complexes in nAMD
P. Almuina Varela Spain
09:18Outcomes of suspending VEGF inhibitors for neovascular age-related macular degeneration when lesions have been inactive for 3 months
M. Gillies Australia
09:24Cellular resolution retinal pigment epithelium imaging with transscleral optical phase imaging (TOPI)
T. Laforest Switzerland
09:30Safety and efficacy of risuteganib in non-exudative age-related macular degeneration – primary results from a phase 2 study
P. Kaiser United States
09:36Efficacy and treatment burden of intravitreal aflibercept vs. ranibizumab treat-and-extend regimens at 24 months: network meta-analysis incorporating individual patient data meta-regression and matching-adjusted indirect comparison
P. Lanzetta Italy
09:42Analysis of the relationship between anatomic control and visual acuity outcomes with anti-VEGF therapy: a post-hoc analysis of catt study data
M. Singer United States
09:48Extended durability in exudative retinal diseases using a new class of molecules: novel anti-VEGF antibody biopolymer conjugate KSI-301: first-time results of the phase 1b study in patients with wAMD, DME and RVO
P. Dugel United States
Back to Previous

Sign up to EURETINA

© EURETINA All rights reserved
Loading please wait